BACKGROUND: The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these alterations in structure and function were associated with cardiovascular morbidity and mortality. METHODS AND RESULTS: The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization. A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between baseline structure and function and patient outcomes were examined using univariate and multivariable Cox proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses controlling for 7 clinical variables (including log N-terminal pro-B-type natriuretic peptide) indicated that increased LV mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart failure events (all P<0.05). CONCLUSIONS:Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF.
RCT Entities:
BACKGROUND: The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these alterations in structure and function were associated with cardiovascular morbidity and mortality. METHODS AND RESULTS: The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization. A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between baseline structure and function and patient outcomes were examined using univariate and multivariable Cox proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses controlling for 7 clinical variables (including log N-terminal pro-B-type natriuretic peptide) indicated that increased LV mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart failure events (all P<0.05). CONCLUSIONS:Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF.
Authors: Sven Meyer; Frank P Brouwers; Adriaan A Voors; Hans L Hillege; Rudolf A de Boer; Ron T Gansevoort; Pim van der Harst; Michiel Rienstra; Isabelle C van Gelder; Dirk J van Veldhuisen; Wiek H van Gilst; Peter van der Meer Journal: Clin Res Cardiol Date: 2014-11-15 Impact factor: 5.460
Authors: Tomohito Ohtani; Selma F Mohammed; Kazuhiro Yamamoto; Shannon M Dunlay; Susan A Weston; Yasushi Sakata; Richard J Rodeheffer; Veronique L Roger; Margaret M Redfield Journal: Eur Heart J Date: 2012-05-29 Impact factor: 29.983
Authors: Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis Journal: Circulation Date: 2019-05-28 Impact factor: 29.690
Authors: Yong Seon Choi; Ana Barbosa Marcondes de Mattos; Dan Shao; Tao Li; Miranda Nabben; Maengjo Kim; Wang Wang; Rong Tian; Stephen C Kolwicz Journal: J Mol Cell Cardiol Date: 2016-09-28 Impact factor: 5.000
Authors: Benjamin M Smith; Steven M Kawut; David A Bluemke; Robert C Basner; Antoinette S Gomes; Eric Hoffman; Ravi Kalhan; João A C Lima; Chia-Ying Liu; Erin D Michos; Martin R Prince; LeRoy Rabbani; Daniel Rabinowitz; Daichi Shimbo; Steven Shea; R Graham Barr Journal: Circulation Date: 2013-03-14 Impact factor: 29.690
Authors: Daisuke Kamimura; Takeki Suzuki; Wanmei Wang; Matthew deShazo; John E Hall; Michael D Winniford; Iftikhar J Kullo; Thomas H Mosley; Kenneth R Butler; Michael E Hall Journal: Hypertens Res Date: 2018-06-15 Impact factor: 3.872